Sengenics

Enabling precision medicine

Company details

Year Aquired

2020

Location

Singapore

Revenue

26 mUSD

Sector

Life Science

Employees

29

Investment Themes

Changing Demographics

Contact

If you want to know more about Sengenics please contact Anna Ryrberg at: anna.ryrberg@summaequity.com

Sengenics at a glance

Sengenics is a proteomics company with a unique technology used to produce full-length, correctly folded, and functional proteins. The technology is leveraged to support pharma and academic research to advance precision medicine through an increased understanding of the autoimmune response in humans. Sengenics’ patented KREX technology enables researchers to detect autoantibodies at high plex levels with high sensitivity. The combination of these capabilities makes KREX unique. There are a broad range of use cases for KREX in research and throughout the value chain for drug response prediction, vaccine testing, and diagnostics. Sengenics is currently focused on measurement of autoantibodies for applications in autoimmune diseases, oncology, and infectious disease. Customers include large pharma, research, and academic institutions, as well as charities and foundations engaged in funding cures for human diseases.

 

Key developments in 2020

The transaction with Summa took much focus in 2020 and closed in October 2020. Covid-19 disrupted pipeline realization, with lockdowns leading to reduced customer activity and unprecedented supply chain issues in shipping and logistics. Considerable progress was made in 2020 on refining the strategy and introducing company-level as well as function-level OKRs for increased clarity and tracking. Sengenics also prepared the launch of various value creation initiatives in 2021. Several key hires were made to strengthen core functions, including a full-time CFO, Global Head of Sales and additional sales team members in the USA, Europe, and Asia. The company has also worked on preparations to set up a new R&D lab in the US during 2021. An enhanced go-to-market strategy and launch plan was developed for the new research tool services and kits initiative, which launched in Q1 2021. A new set of ESG policies and frameworks have also been implemented.

Impact dimensions

The challenges we face

We currently suffer from ineffective medication due to a lack of understanding of the biology of diseases. The shift from the "one size fits all" approach to precision medicine is a colossal challenge for science. Development of autoantibody biomarker signatures enables improved understanding of human biology and can optimize the development of safer and higher efficacy drugs, hence enabling healthcare to become more personalized and for the right treatment to be delivered to the right patient at the appropriate time.

What is the outcome?

Sengenics contributes to the understanding of human biology through its unique proteomics technology. Sengenics’ technology enables biological response research at high sensitivity and specificity, thereby contributing to the development of more targeted, efficient and effective therapeutics, vaccines and diagnostics. Sengenics' technology is also a key enabler for personalized medicine.

Who are the stakeholders?

Sengenics' customers are primarily found in pharma and in academic centers, who are focused on drug discovery and understanding of biology in human disease. Sengenics’ technology can enable these customers to drive the future of precision medicine. Consequently, the efficacy, affordability and accessibility of drugs will increase, ultimately providing great benefit to individual patients and health systems at large. The ultimate vision is to impact the decisions made by healthcare payors, namely medical insurance companies, federal healthcare systems and ultimately individual patients and doctors.

How big is the effect, and does it last?

Sengenics currently has commercial partnerships with 9 out of the top 10 pharma to co-develop complementary and companion diagnostic tests for autoimmune and cancer immunotherapy drugs, holds 17 patents, has been featured in over 23 publications and has completed more than 100 research projects worldwide.

If Sengenics didn't exist...

Sengenics's technology is truly unique, providing insights that drive biological research forward, hence making a great contribution to the field of precision medicine. Specifically, this involves improving the understanding of the human proteome and immune system. If Sengenics did not exist, a vast majority of the research that it enables today would not be done or would require a lot more complexity and cost with less precise results.

Impact risk: what can go wrong?

Product quality and reproducibility are fundamentally important, so if Sengenics would be unable to deliver strong product quality, its customers would likely stop using its products.

Year Aquired

2020

Revenue

26 mUSD

Employees

29

Investment Themes

Changing Demographics

Sector

Life Science

Location

Singapore

Contact

If you want to know more about Sengenics please contact Anna Ryrberg at: anna.ryrberg@summaequity.com

Website

Video

SDG Alignment
SDG Wheel
SDG 3
KPI reporting
SDG 8

REVENUE (SEKm)

2020
26 (-40%)
2019
43
SDG 3

Accumulated no. of publications

2020
35%
23
2019
17